Immplacate, Inc. is a pre-clinical stage cell therapy company that aims to provide a safe and effective therapy that will reduce morbidity and mortality from immune disorders. By taking advantage of the latest science in mesenchymal stem cell biology, we have designed an educated mesenchymal cell (EMSC) therapy, which will have higher potency than competing MSC therapies while maintaining an excellent safety profile.

We have recruited a well-balanced senior management team and BOD to lead our company. We are pursuing seed funding and moving to JLABS, NYC location In October, 2018 to further our project in an environment set up to provide leverage for resources and industry contacts. To that end, we have signed a key strategic partner that is a recognized, global cell therapy industry leader in Daewoong Pharmaceutical Inc. Daewoong has taken an equity stake in Immplacate contributing $1mm USD and other resources and will retain a board seat at the firm. In addition, we have recruited a top-notch list of scientific and clinical advisors familiar with this market.

Upon completion of our clinical trails and following FDA approval, we will market our offering to physicians and hospitals via distribution on a global scale. We will also look to license our technology to various markets and strategic partners. Our initial target market will be GvHD related to BMT. This is a robust market both in the USA and abroad, and will serve as a base upon which we will build other indications for EMSC therapy.